-
Mashup Score: 44Improving the Detection of Potential Cases of Familial Hypercholesterolemia: Could Machine Learning Be Part of the Solution? - 9 month(s) ago
BackgroundFamilial hypercholesterolemia (FH), while highly prevalent, is a significantly underdiagnosed monogenic disorder. Improved detection could reduce the large number of cardiovascular events…
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2EAS Newsletter June 4, 2024 - 9 month(s) ago
Congress: We would like to extend our heartfelt gratitude to each and every one of you who joined us for the EAS Congress 2024. Whether this was your first time attending or you have been with us for…
Source: eas-society.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 6Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION‐9, ORION‐10 and ORION‐11 Phase 3 randomized trials - 10 month(s) ago
Diabetes, Obesity & Metabolism is an interdisciplinary journal for clinical & experimental pharmacology and therapeutics relating to metabolic & endocrine disease.
Categories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION‐9, ORION‐10 and ORION‐11 Phase 3 randomized trials - 10 month(s) ago
Diabetes, Obesity & Metabolism is an interdisciplinary journal for clinical & experimental pharmacology and therapeutics relating to metabolic & endocrine disease.
Categories: General Medicine News, CardiologistsTweet
-
Mashup Score: 28Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial - 10 month(s) ago
AbstractBackground and aims. Data describing the long-term efficacy, safety, and tolerability of inclisiran are limited. This was explored in ORION-8, an o
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 27Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial - 10 month(s) ago
AbstractBackground and aims. Data describing the long-term efficacy, safety, and tolerability of inclisiran are limited. This was explored in ORION-8, an o
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 37
Inclisiran, an siRNA therapy, consistently reduces low-density lipoprotein cholesterol (LDL-C) with twice-yearly dosing. Potential cardiovascular bene…
Source: www.sciencedirect.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 54
Patients with heterozygous familial hypercholesterolemia (HeFH) often cannot reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) g…
Source: www.sciencedirect.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 54
Patients with heterozygous familial hypercholesterolemia (HeFH) often cannot reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) g…
Source: www.sciencedirect.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 42
Patients with heterozygous familial hypercholesterolemia (HeFH) often cannot reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) g…
Source: www.sciencedirect.comCategories: General Medicine News, CardiologistsTweet
Our latest publication out in JAHA today and open access. Great work by Christophe Stevens as part of his PhD. Improving the screening of potential cases for FH to prioritise who to refer for genetic testing. https://t.co/fNyOF4ruh6